[{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioDelivery Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"12","companyTruncated":"Titan Pharmaceuticals Inc \/ Indegene Inc"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Molteni Farmaceutici"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"TAIWAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Alar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"Lyndra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Lyndra Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended release Capsule","sponsorNew":"Lyndra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Lyndra Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Alvogen","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Alvogen","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Alvogen"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Collegium"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"Emplicure","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Emplicure","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emplicure \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Emplicure \/ Quotient Sciences"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"BioDelivery Sciences","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"BioDelivery Sciences","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.59999999999999998,"dosageForm":"Buccal Film","sponsorNew":"BioDelivery Sciences \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"BioDelivery Sciences \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Quotient Sciences","sponsor":"Emplicure","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Quotient Sciences \/ Emplicure","highestDevelopmentStatusID":"6","companyTruncated":"Quotient Sciences \/ Emplicure"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Xiromed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Xiromed","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Xiromed"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ Not Applicable"},{"orgOrder":0,"company":"Xiromed","sponsor":"IntelGenx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Xiromed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film","sponsorNew":"Xiromed \/ IntelGenx","highestDevelopmentStatusID":"10","companyTruncated":"Xiromed \/ IntelGenx"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Buprenorphine
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Quotient Sciences- Molecule to Cure. Fast.
